Kymera Therapeutics, Inc.
Tricyclic CRBN ligands and uses thereof
Last updated:
Abstract:
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.
Status:
Grant
Type:
Utility
Filling date:
3 Jul 2019
Issue date:
5 Apr 2022